The role of diabetes in cardiomyopathies of different etiologies-Characteristics and 1-year follow-up results of the EVITA-HF registry.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 19 03 2020
accepted: 21 05 2020
entrez: 12 6 2020
pubmed: 12 6 2020
medline: 25 8 2020
Statut: epublish

Résumé

Type 2 diabetes is a major risk factor for cardiovascular diseases, e.g. coronary artery disease (CAD). But it has also been shown that diabetes can cause heart failure independently of ischemic heart disease (IHD) by causing diabetic cardiomyopathy. In contrast to diabetes and IHD, limited data exist regarding patients with diabetes and dilated cardiomyopathy (DCM). EVIdence based TreAtment in Heart Failure (EVITA-HF) comprises web-based case report data on demography, diagnostic measures, adverse events and 1-year follow-up of patients hospitalized for chronic heart failure and an ejection fraction ≤40%. In the present study we focused on the results of patients with diabetes and heart failure. Between February 2009 and November 2015, 4101 patients with chronic heart failure were included in 16 tertiary care centers in Germany. The mortality in patients with diabetes and DCM (n = 323) was more than double (15.2%) than that of DCM patients without diabetes (6.5%, p<0.001, n = 885). In contrast the mortality rate of patients with IHD was not influenced by the presence of diabetes (17.6% in patients with IHD and diabetes n = 945, vs. 14.7% in patients with IHD and no diabetes, n = 1236, p = 0.061). The results also remained stable after performing a multivariable analysis (unadjusted p-value for interaction = 0.002, adjusted p = 0.046). The influence of diabetes on the mortality rate is only significant in patients with DCM not in patients with CAD. Therefore, the underlying mechanisms of this effect should be studied in greater detail to improve patient care and outcome.

Sections du résumé

BACKGROUND
Type 2 diabetes is a major risk factor for cardiovascular diseases, e.g. coronary artery disease (CAD). But it has also been shown that diabetes can cause heart failure independently of ischemic heart disease (IHD) by causing diabetic cardiomyopathy. In contrast to diabetes and IHD, limited data exist regarding patients with diabetes and dilated cardiomyopathy (DCM).
METHODS
EVIdence based TreAtment in Heart Failure (EVITA-HF) comprises web-based case report data on demography, diagnostic measures, adverse events and 1-year follow-up of patients hospitalized for chronic heart failure and an ejection fraction ≤40%. In the present study we focused on the results of patients with diabetes and heart failure.
RESULTS
Between February 2009 and November 2015, 4101 patients with chronic heart failure were included in 16 tertiary care centers in Germany. The mortality in patients with diabetes and DCM (n = 323) was more than double (15.2%) than that of DCM patients without diabetes (6.5%, p<0.001, n = 885). In contrast the mortality rate of patients with IHD was not influenced by the presence of diabetes (17.6% in patients with IHD and diabetes n = 945, vs. 14.7% in patients with IHD and no diabetes, n = 1236, p = 0.061). The results also remained stable after performing a multivariable analysis (unadjusted p-value for interaction = 0.002, adjusted p = 0.046).
CONCLUSION
The influence of diabetes on the mortality rate is only significant in patients with DCM not in patients with CAD. Therefore, the underlying mechanisms of this effect should be studied in greater detail to improve patient care and outcome.

Identifiants

pubmed: 32525964
doi: 10.1371/journal.pone.0234260
pii: PONE-D-20-07928
pmc: PMC7289353
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0234260

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

ESC Heart Fail. 2018 Aug;5(4):642-648
pubmed: 30117720
Lancet. 2001 Aug 11;358(9280):439-44
pubmed: 11513906
Circ Res. 2015 Mar 27;116(7):1254-68
pubmed: 25814686
Diabetes Obes Metab. 2007 May;9(3):323-9
pubmed: 17391158
Circulation. 1999 Dec 7;100(23):2312-8
pubmed: 10587334
Circulation. 2003 Mar 25;107(11):1486-91
pubmed: 12654604
Eur Heart J. 2000 Aug;21(16):1368-75
pubmed: 10952826
Eur J Heart Fail. 2008 Mar;10(3):298-307
pubmed: 18296111
Diabetol Metab Syndr. 2018 Mar 15;10:19
pubmed: 29568331
Circ Heart Fail. 2016 Jan;9(1):
pubmed: 26754626
Circ Res. 2016 Jun 24;119(1):91-112
pubmed: 27340270
Can J Diabetes. 2013 Apr;37 Suppl 1:S126-8
pubmed: 24070934
Circulation. 2007 Jun 26;115(25):3213-23
pubmed: 17592090
Eur Heart J. 2008 Jun;29(11):1377-85
pubmed: 18413309
Am J Cardiol. 1972 Nov 8;30(6):595-602
pubmed: 4263660
Am Heart J. 2003 Nov;146(5):848-53
pubmed: 14597934
Lancet. 2010 Sep 11;376(9744):875-85
pubmed: 20801500
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Eur J Echocardiogr. 2006 Jan;7(1):40-4
pubmed: 15886060
Eur Heart J. 2000 Dec;21(23):1967-78
pubmed: 11071803
Clin Res Cardiol. 2014 Dec;103(12):1006-14
pubmed: 25052361
Eur Heart J. 2015 Jul 14;36(27):1718-27, 1727a-1727c
pubmed: 25888006
Eur J Heart Fail. 2018 May;20(5):853-872
pubmed: 29520964
Circulation. 2008 Jan 1;117(1):43-51
pubmed: 18071071
J Am Coll Cardiol. 1996 Apr;27(5):1201-6
pubmed: 8609343
N Engl J Med. 2013 May 9;368(19):1845-6
pubmed: 23656658
N Engl J Med. 2020 Mar 5;382(10):973
pubmed: 32130823
J Card Fail. 2016 Jul;22(7):485-91
pubmed: 26687984
Circulation. 2015 Mar 17;131(11):1019-30
pubmed: 25779542
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Lancet. 2005 May 28-Jun 3;365(9474):1877-89
pubmed: 15924986
Diabetes Care. 2005 Mar;28(3):612-6
pubmed: 15735197
J Am Coll Cardiol. 2006 Oct 17;48(8):1548-51
pubmed: 17045886
Circulation. 2018 Jan 23;137(4):323-334
pubmed: 29133604
Diabetes. 2013 Oct;62(10):3329-30
pubmed: 24065790
Eur J Heart Fail. 2018 Dec;20(12):1690-1700
pubmed: 30328645
J Am Coll Cardiol. 1996 Oct;28(4):964-71
pubmed: 8837575
Lancet. 2014 Mar 22;383(9922):1068-83
pubmed: 24315620
J Card Fail. 2007 Nov;13(9):769-73
pubmed: 17996827

Auteurs

Christine Meindl (C)

Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.

Matthias Hochadel (M)

Stiftung Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.

Lutz Frankenstein (L)

Department of Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany.

Oliver Bruder (O)

Department of Cardiology and Angiology, Elisabeth-Hospital Essen, Essen, Germany.

Matthias Pauschinger (M)

Department of Internal Medicine 8, Nürnberg Hospital, Nürnberg, Germany.

Rainer Hambrecht (R)

Department of Internal Medicine II, Hospital Links der Weser, Bremen, Germany.

Wolfgang von Scheidt (W)

Department of Internal Medicine I, University Hospital Augsburg, Augsburg, Germany.

Otmar Pfister (O)

Department of Cardiology, University Hospital Basel, Basel, Switzerland.

Andreas Hartmann (A)

Department of Cardiology and Internal Intensive Care, St. Georg Hospital Leipzig, Leipzig, Germany.

Lars S Maier (LS)

Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.

Jochen Senges (J)

Stiftung Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany.

Bernhard Unsöld (B)

Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH